Christopher Münch is director of the Cardiac Anesthesia and Intensive Care Department since 2013. Since 2016 a minimal invasive cardiac surgery program was started in the department with special attention to ultrafast track anesthesia after mitral valve surgery. The center treats approximately 1200 adult patients/year addressing all major cardiac pathologies except heart transplantation. Recently, regional anesthesia techniques were integrated in the daily practice and all minimal invasive surgical patients are treated with regional chest blocks. A web-based patient platform has been developed in collaboration with the Polytechnical University of Marche to further improve patients experience and to enhance perioperative fitness of the patients. The Cardiac Center of Ancona receives extensive visiting from surgeons and anesthetists from all over the world who are interested in appraising the details of fast track protocols

John R. Dylewski, MD, FHRS, FACPAS  is a cardiac electro physiologist and professor of medicine in active clinical practice for the last 20+ years with an extensive and diversified background in materials engineering and medical applications of artificial intelligence to improve healthcare delivery. With the abundance of valuable data generated for patient care and the continuous production of scientific knowledge, Dr. Dylewski found it significantly challenging to deliver accurate, up-to-date and expeditious care to his tens of thousands of patients resulting in the development of the Complaint2Care model for a novel healthcare delivery platform, LifeSaver, powered by Apollo Artificial Intelligence. 

Dipak Ramji is Professor of Cardiovascular Science and Deputy Head at the School of Biosciences in Cardiff University. He is also Fellow of the Learned Society of Wales. He received his BSc (Hons) degree (Biochemistry) and his PhD (Molecular Biology) from the University of Leeds. This was followed by post-doctoral research at EMBL (Heidelberg) and IRBM (Rome) with fellowships from the Royal Society and the EU. His current research is focused on understanding how natural products regulate cellular processes in heart disease with the goal of attaining deeper mechanistic insight and identifying preventative/therapeutic agents. He has published over 150 research articles (h index 41 and i10 index 76 with over 8350 citations), including 880-page book in 2022 on Methods in Atherosclerosis. He is an Editorial Board member of 16 international journals; regular organising committee member, speaker, and track/session chair at international conferences on heart disease; involved in grant evaluation for over 20 organisations; and supervised over 25 PhD students

Steven J. Adelman, Founder and CEO of Vascular Strategies LLC, and CSO, NanoPhagix LLC has more than 25 years’ experience in drug discovery and development. Previously led several initiatives at Wyeth Pharmaceuticals: Senior Director, Cardiovascular and Metabolic Disease Research and Senior Director, Atherosclerosis CV/Women’s Health. Activities included identifying and validating discovery and development programs (small molecules and biologics), advancing more than 10 compounds through IND into clinical development. Expertise includes atherosclerosis and CVD, inflammation, immune biology, and women’s health. Worked extensively on rapamycin (sirolimus, Rapamune) for transplant indications and subsequent incorporation on the Cypher-stent, first successful drug-eluting coronary stent. Honors and memberships include elected Fellow American Heart Association; Golden Heart Member, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Basic Sciences Council, Functional Genomics and Translational Biology Interdisciplinary Working Group, AHA, and International Atherosclerosis Society. Authored more than 100 articles and abstracts and holds over 30 patents.

John K Maesaka was born in Hawaii, received degrees from Harvard College and Boston University School of Medicine, did his medical residencies at BarnesJewish Hospital at Washington University In St. Louis and Mount Sinai Hospital in New York and renal fellowship at Mount Sinai Hospital. His interest-driven decision to spend 5 years exclusively in the renal physiology laboratory at Mount Sinai Hospital as a renal fellow and member of the faculty proved to be the best investment he made to pursue an academic career in medicine. He was involved in developing colorimetric methods for the determination of uric acid and phosphorus in blood and urine that were applied to studying the transport characteristics of both electrolytes by renal micropuncture techniques in rat kidney. He developed several bioassays to demonstrate the presence of a natriuretic factor in the blood of patients with renal salt wasting and Alzheimer’s disease and more recently identified the elusive natriuretic factor after more than a 25-year pursuit.